November 17, 2009 (Orlando, Florida) — Advanced heart-failure transplant-ineligible patients with Thoratec's HeartMate II continuous-flow left-ventricular assist device (LVAD) have better-than-even ...

January 21, 2010 (Silver Spring, Maryland) — Thoratec's HeartMate II is the first continuous-flow left-ventricular assist device (LVAD) approved by the FDA for transplant-ineligible heart-failure ...

PLEASANTON, Calif., May 3, 2011 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts ...

Please provide your email address to receive an email when new articles are posted on . A new bridge-to-transplant technology is now available for patients in need of a left ventricular assist device.

In cases of extreme cardiogenic shock or very high intervention risk owing to anatomical complexity, PCI with support from a percutaneous left ventricular assist device is a viable revascularization ...

In the ROADMAP study, patients with a HeartMate II ™ LVAD had a functional improvement in quality of life compared to optimal medical management The ROADMAP study was a prospective, multi-center ...

Thoratec's HeartMate II left ventricular assist device--Courtesy of Thoratec Thoratec ($THOR) said that two patients died and one suffered a serious injury after they ...

Thoratec ($THOR) credited a U.S. and global sales surge of its HeartMate II pump as a key factor in boosting 2012 first-quarter revenue 27% versus a year earlier. As ...

NEW ORLEANS, LA—Final, full results from the MOMENTUM 3 trial show that the HeartMate 3 magnetically levitated, centrifugal-flow left ventricular assist device (LVAD) is superior to the ...

There are more people in need of new hearts than there are hearts available — that's a big reason companies like Abbott Laboratories and Medtronic sell advanced implantable pumps called ...